Skip to main content
SSO 2024 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded for On-Demand Viewing
Recorded for On-Demand Viewing
Back

Melanoma Great Debate: Targeted versus Complete Nodal Dissection following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold off on Continued De-escalation of Surgery?

Pro/Affirmative

Thursday, March 21, 2024
10:37am – 10:52am ET
Location: C101

    Debater - Pro(s)

  • Alexander C.J van Akkooi, MD, PhD (he/him/his)

    Surgical Oncologist
    Melanoma Institute Australia / University of Sydney, Faculty of Medicine and Health / Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology
    Sydney, New South Wales, Australia

Disclosure(s):
Alexander C.J van Akkooi, MD, PhD: 4SC: Advisor (Ongoing), Consultant (Ongoing); Amgen: Advisor (Ongoing), Consultant (Ongoing), Research Grant (Ongoing); Bristol Myers Squibb: Advisor (Ongoing), Consultant (Ongoing); Merck Serono: Advisor (Ongoing), Consultant (Ongoing), Research Grant (Ongoing); Merck Sharp & Dohme: Advisor (Ongoing), Consultant (Ongoing); NeraCare: Advisor (Ongoing), Consultant (Ongoing); Novartis: Advisor (Ongoing), Consultant (Ongoing); Pierre Fabre: Advisor (Ongoing), Consultant (Ongoing); Provectus: Advisor (Ongoing), Consultant (Ongoing); Sanofi/ Regeneron: Advisor (Ongoing), Consultant (Ongoing); Sirius medical: Advisor (Ongoing), Consultant (Ongoing)
Neoadjuvant immunotherapy has been increasingly adopted for the treatment of patients with clinically apparent stage 3 disease. As this becomes increasingly adopted, it is unclear if targeted lymph node removal, albeit potentially prognostic, is sufficient to manage the regional nodal basin. This debate will highlight the evidence for this approach and future directions in the field of neoadjuvant immunotherapy for the treatment of melanoma.